专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110086004A1 METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY 审中-公开
公开(公告)号：US20110086004A1
公开(公告)日：2011-04-14
申请号：US12947957
申请日：2010-11-17
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
IPC分类号： A61K38/20 , A61P35/00 , A61P37/04
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.

2. 发明申请

US20090087404A1 METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY 审中-公开
公开(公告)号：US20090087404A1
公开(公告)日：2009-04-02
申请号：US12250911
申请日：2008-10-14
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
IPC分类号： A61K38/20 , A61P35/00
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.

3. 发明申请

US20110300098A1 METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY 审中-公开
标题翻译：使用IL-21和单克隆抗体治疗癌症治疗方法
公开(公告)号：US20110300098A1
公开(公告)日：2011-12-08
申请号：US12826099
申请日：2010-06-29
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
IPC分类号： A61K38/20 , A61P35/00
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
摘要翻译：描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。

4. 发明授权

US5641655A Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide 失效
标题翻译：使用哺乳动物组织纤溶酶原激活物分泌肽产生血小板生成素多肽的方法
公开(公告)号：US5641655A
公开(公告)日：1997-06-24
申请号：US347029
申请日：1994-11-30
申请人： Donald C. Foster , Mark D. Heipel , Richard D. Holly
发明人： Donald C. Foster , Mark D. Heipel , Richard D. Holly
IPC分类号： C12N15/09 , C07K14/47 , C07K14/52 , C12N1/19 , C12N5/10 , C12N9/72 , C12N15/62 , C12P21/02 , C12R1/865 , C12N15/19 , C07H21/04
CPC分类号： C12N9/6459 , C07K14/524 , C12N15/625 , C12Y304/21069 , C07K2319/02 , C07K2319/036 , C07K2319/50 , C07K2319/75
摘要： DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined to a thrombopoietin polypeptide and one or more additional DNA segments that provide for the transcription of the first segment. The secretory peptide is a native mammalian t-PA secretory peptide or may be modified to enhance proteolytic cleavage of the fusion. Also disclosed are cultured eukaryotic cells containing these DNA constructs and methods for producing thrombopoietin polypeptides through the use of the DNA constructs and cultured eukaryotic cells.
摘要翻译：公开了可用于生产血小板生成素的DNA构建体。通常，DNA构建体包含编码与血小板生成素多肽连接的氨基末端分泌肽与提供第一片段转录的一个或多个另外的DNA片段的融合物的第一DNA片段。分泌肽是天然哺乳动物的t-PA分泌肽，或可以被修饰以增强融合物的蛋白水解切割。还公开了含有这些DNA构建体的培养真核细胞和通过使用DNA构建体和培养的真核细胞产生血小板生成素多肽的方法。

5. 发明申请

US20120208772A1 CYTOKINE ZALPHA11 LIGAND 有权
公开(公告)号：US20120208772A1
公开(公告)日：2012-08-16
申请号：US13339639
申请日：2011-12-29
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： A61K38/17 , A61P37/02 , A61P7/00 , C07K14/435 , C07K17/08
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译：描述了与SEQ ID NO：2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。抗体可以结合162个氨基酸残基或其片段的全长序列，包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。抗体可以包括多克隆，单克隆，鼠，人源化或中和的抗体。还描述了产生抗体的方法。

6. 发明授权

US08110180B2 Method of use of cytokine ZALPHA11 ligand 有权
标题翻译：细胞因子ZALPHA11配体的使用方法
公开(公告)号：US08110180B2
公开(公告)日：2012-02-07
申请号：US11551356
申请日：2006-10-20
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： A61K45/00 , A61K35/12 , A61K38/00 , A61K38/16
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译：描述了与SEQ ID NO：2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。抗体可以结合162个氨基酸残基或其片段的全长序列，包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。抗体可以包括多克隆，单克隆，鼠，人源化或中和的抗体。还描述了产生抗体的方法。

7. 发明授权

US07572892B2 Cytokine zalpha11 ligand fusion proteins 有权
公开(公告)号：US07572892B2
公开(公告)日：2009-08-11
申请号：US11551820
申请日：2006-10-23
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： C07K14/52 , C07K14/00 , C12N15/00 , A61K39/00
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.

8. 发明授权

US06307024B1 Cytokine zalpha11 Ligand 有权
标题翻译：细胞因子zalpha11配体
公开(公告)号：US06307024B1
公开(公告)日：2001-10-23
申请号：US09522217
申请日：2000-03-09
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： C07K1400
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
摘要翻译：本发明涉及zalpha11配体多核苷酸和多肽分子。 zalpha11配体是一种新型细胞因子。多肽可用于在体外和体内刺激造血细胞的增殖和/或发育的方法中。本发明还包括生产蛋白质的方法，其用途及其抗体。

9. 发明授权

US5753224A Hybrid protein C 失效
标题翻译：杂交蛋白C
公开(公告)号：US5753224A
公开(公告)日：1998-05-19
申请号：US463585
申请日：1995-06-05
申请人： Donald C. Foster , Richard D. Holly
发明人： Donald C. Foster , Richard D. Holly
IPC分类号： C12N9/60 , C12N9/64 , A61K38/00 , A61K35/14 , A61K38/48 , G01N33/53
CPC分类号： C12N9/6464 , C12N9/60 , C12Y304/21069 , C07K2319/00
摘要： Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof. The modified molecules, having an increased half-life in human plasma, are particularly useful for treating coagulation-related disorders, such as protein C deficiency or thrombosis, or for promoting fibrinolysis in a patient.
摘要翻译：人蛋白C分子被修饰以提供对人血浆因子的失活增强的抗性，同时保留人蛋白C的生物活性。修饰通常是蛋白C的重链，该链可被C蛋白重链取代非人源的，如牛，产生嵌合蛋白C分子。人蛋白C重链也可以被修饰为人样，因为来自非人序列的至少一个氨基酸可以被人序列的相应残基取代，从而允许分子保留基本上人的特征，但具有增加的失活抗性。还包括生产修饰的蛋白C分子的方法及其药物组合物。在人血浆中具有增加的半衰期的改性分子对于治疗凝血相关疾病如蛋白C缺乏或血栓形成或促进患者的纤维蛋白溶解特别有用。

10. 发明授权

US07829075B2 Method for expanding hematopoietic cells using cytokine zalpha11 ligand 有权
标题翻译：使用细胞因子zalpha11配体扩增造血细胞的方法
公开(公告)号：US07829075B2
公开(公告)日：2010-11-09
申请号：US11551127
申请日：2006-10-19
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： A61K38/20 , C07K14/54
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译：描述了与SEQ ID NO：2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。抗体可以结合162个氨基酸残基或其片段的全长序列，包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。抗体可以包括多克隆，单克隆，鼠，人源化或中和的抗体。还描述了产生抗体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式